Impact of Bone Marrow Aspirate Tregs on the Response Rate of Younger Newly Diagnosed Acute Myeloid Leukemia Patients

Figure 2

(a) Diagnostic bone marrow aspirate (dBMA) CD4-lymphocyte correlation with Tregs (, ). (b) Median dBMA Treg value in responder and nonresponder patients (28 versus 13/μL, Mann–Whitney rank sum test, ). (c) ROC curve: AUC analysis (AUC, 0.80; 95% CI, 0.5902–0.9791, ), 21/μL, optimal dBMA Treg cut-off value for predicting response to treatment, yielding 77% sensitivity (95% CI, 53% to 92%) and 80% specificity (95% CI, 44% to 97%). (d) Median OS in ≥21/μL and <21/μL dBMA Tregs (18 versus 5 months, log-rank test, ).

(a)

(b)

(c)

(d)